The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
Open accessAbstract
Huntington's disease (HD), an inherited neurodegenerative disorder, is caused by an abnormal polyglutamine expansion in the huntingtin protein. This genetic defect may result in heightened neuronal susceptibility to excitotoxic injury, a mechanism that has been postulated to play a critical role in HD. Quinolinate (QUIN) and kynurenate (KYNA), two endogenous neuroactive metabolites of the kynurenine pathway of tryptophan degradation, have been proposed to modulate excitotoxic neuronal death in HD. A third kynurenine pathway metabolite, the free radical generator 3-hydroxykynurenine (3-HK), has also been hypothesized to play a causal role in the pathogenesis of HD. We show here that the brain levels of both 3-HK and QUIN are increased three to four-fold in low-grade (grade 0/1) HD brain. These changes were seen in the neocortex and in the neostriatum, but not in the cerebellum. In contrast, brain 3-HK and QUIN levels were either unchanged or tended to decrease in grade 2 and advanced grade (grades 3-4) HD brain. Brain kynurenine and KYNA levels fluctuated only modestly as the illness progressed. These results support a possible involvement of 3-HK and QUIN in the early phases of HD pathophysiology and indicate novel therapeutic strategies against the disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Self-citationEarly mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Free Radical Pathways in CNS Injury
LEWÉN, A., MATZ, P., & CHAN, P. H. (2000) · Journal of Neurotrauma · doi:10.1089/neu.2000.17.871 · Cited by 759
HEYES, M. P., SAITO, K., CROWLEY, J. S., DAVIS, L. E., DEMITRACK, M. A., DER, M., DILLING, L. A., ELIA, J., KRUESI, M. J. P., LACKNER, A., et al. (1992) · Brain · doi:10.1093/brain/115.5.1249 · Cited by 680
Stipe, J., White, D., & Arsdale, E. V. (1979) · The American Journal of Nursing · doi:10.2307/3424618 · Cited by 602
Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., Hayden, M. R., & Raymond, L. A. (2002) · Neuron · doi:10.1016/s0896-6273(02)00615-3 · Cited by 595
Manipulation of Brain Kynurenines: Glial Targets, Neuronal Effects, and Clinical Opportunities
Schwarcz, R., & Pellicciari, R. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.034439 · Cited by 556
Self-citationEarly and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain
Sapp, E., Kegel, K. B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P. G., Vonsattel, J. P., & Difiglia, M. (2001) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/60.2.161 · Cited by 540
Huntingtin aggregation and toxicity in Huntington's disease
Bates, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13304-1 · Cited by 525
Evidence for more widespread cerebral pathology in early HD: An MRI-based morphometric analysis
Rosas, H. D., Koroshetz, W. J., Chen, Y. I., Skeuse, C., Vangel, M., Cudkowicz, M. E., Caplan, K., Marek, K., Seidman, L. J., Makris, N., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000065888.88988.6e · Cited by 505
Foster, A. C., Vezzani, A., French, E. D., & Schwarcz, R. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90050-8 · Cited by 434
Self-citationLevine, M. S., Klapstein, G. J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M. E., Jokel, E. S., Carpenter, E. M., Zanjani, H., Hurst, R. S., et al. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991115)58:4<515::aid-jnr5>3.0.co;2-f · Cited by 352
Neuropathogenic Forms of Huntingtin and Androgen Receptor Inhibit Fast Axonal Transport
Szebenyi, G., Morfini, G. A., Babcock, A., Gould, M., Selkoe, K., Stenoien, D. L., Young, M., Faber, P. W., MacDonald, M. E., McPhaul, M. J., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00569-5 · Cited by 326
Cepeda, C., Hurst, R. S., Calvert, C. R., Hernández-Echeagaray, E., Nguyen, O. K., Jocoy, E., Christian, L. J., Ariano, M. A., & Levine, M. S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-00961.2003 · Cited by 321
Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice
Liévens, J.-C., Woodman, B., Mahal, A., Spasic-Boscovic, O., Samuel, D., Kerkerian-Le Goff, L., & Bates, G. P. (2001) · Neurobiology of Disease · doi:10.1006/nbdi.2001.0430 · Cited by 313
Beal, M. F., Matson, W. R., Swartz, K. J., Gamache, P. H., & Bird, E. D. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb03143.x · Cited by 311
Okuda, S., Nishiyama, N., Saito, H., & Katsuki, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.22.12553 · Cited by 301
Laforet, G. A., Sapp, E., Chase, K., McIntyre, C., Boyce, F. M., Campbell, M., Cadigan, B. A., Warzecki, L., Tagle, D. A., Reddy, P. H., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09112.2001 · Cited by 290
NMDA receptor function in mouse models of Huntington disease
Cepeda, C., Ariano, M. A., Calvert, C. R., Flores‐Hernández, J., Chandler, S. H., Leavitt, B. R., Hayden, M. R., & Levine, M. S. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1244 · Cited by 274
Quinolinic acid is a potent lipid peroxidant in rat brain homogenates
Rios, C., & Santamaria, A. (1991) · Neurochemical Research · doi:10.1007/bf00966592 · Cited by 271
Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex
Flint Beal, M., Matson, W. R., Storey, E., Milbury, P., Ryan, E. A., Ogawa, T., & Bird, E. D. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90191-m · Cited by 218
3-Hydroxyanthranilate oxygenase activity is increased in the brains of Huntington disease victims.
Schwarcz, R., Okuno, E., White, R. J., Bird, E. D., & Whetsell, W. O. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.11.4079 · Cited by 184
Self-citation3‐Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum
Guidetti, P., & Schwarcz, R. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00806.x · Cited by 180
Self-citationWhetsell, W. O., & Schwarcz, R. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90609-5 · Cited by 175
Self-citationHansson, O., Guatteo, E., Mercuri, N. B., Bernardi, G., Li, X., Castilho, R. F., & Brundin, P. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01767.x · Cited by 165
Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease
Pearson, S. J., & Reynolds, G. P. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90749-w · Cited by 155
Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release.
Li, H., Wyman, T., Yu, Z.-X., Li, S.-H., & Li, X.-J. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg218 · Cited by 155
Ginés, S., Ivanova, E. V., Seong, I., Saura, C. A., & MacDonald, M. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309348200 · Cited by 136
Butterfield, D. A., Howard, B. J., & LaFontaine, M. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013373048 · Cited by 134
Kerr, S. J., Armati, P. J., Guillemin, G. J., & Brew, B. J. (1998) · AIDS · doi:10.1097/00002030-199804000-00003 · Cited by 132
Jauch, D., Urbańska, E. M., Guidetti, P., Bird, E. D., Vonsattel, J., Whetsell, W. O., & Schwarcz, R. M. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)00280-2 · Cited by 127
Self-citationRole of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease
Li, L., Fan, M., Icton, C. D., Chen, N., Leavitt, B. R., Hayden, M. R., Murphy, T. H., & Raymond, L. A. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.04.003 · Cited by 127
Kynurenate production by cultured human astrocytes
Kiss, C., Ceresoli‐Borroni, G., Guidetti, P., Zielke, C. L., Zielke, H. R., & Schwarcz, R. M. (2003) · Journal of Neural Transmission · doi:10.1007/s00702-002-0770-z · Cited by 121
Self-citationBrain Quinolinic Acid in Huntington's Disease
Reynolds, G. P., Pearson, S. J., Halket, J. M., & Sandier, M. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb02503.x · Cited by 109
Chiarugi, A., Meli, E., & Moroni, F. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00335.x · Cited by 108
Uptake of Kynurenine into Rat Brain Slices
Speciale, C., & Schwarcz, R. M. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb13296.x · Cited by 107
Self-citationLuthi-Carter, R., Apostol, B. L., Dunah, A. W., DeJohn, M. M., Farrell, L. A., Bates, G. P., Young, A. B., Standaert, D. G., Thompson, L. M., & Cha, J.-H. J. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.024 · Cited by 104
Self-citationMacDonald, M. E., Ginés, S., Gusella, J. F., & Wheeler, V. C. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:4:1-2:7 · Cited by 104
Astrocyte Modulation of Neurotoxic Injury
Aschner, M., Sonnewald, U., & Tan, K. H. (2002) · Brain Pathology · doi:10.1111/j.1750-3639.2002.tb00465.x · Cited by 103
Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia
Schwarcz, R. M., Tamminga, C. A., Kurlan, R., & Shoulson, I. (1988) · Annals of Neurology · doi:10.1002/ana.410240417 · Cited by 102
Self-citationEarly kynurenergic impairment in Huntington's Disease and in a transgenic animal model
Guidetti, P., Reddy, P. H., Tagle, D. A., & Schwarcz, R. M. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00956-3 · Cited by 97
Self-citationVazquez, S., Garner, B., Sheil, M. M., & Truscott, R. J. W. (2000) · Free Radical Research · doi:10.1080/10715760000300021 · Cited by 95
Foster, A. C., Whetsell, W. O., Bird, E. D., & Schwarcz, R. M. (1985) · Brain Research · doi:10.1016/0006-8993(85)90647-x · Cited by 83
Self-citationWu, H., Guidetti, P., Goodman, J. H., Varasi, M., Ceresoli‐Borroni, G., Speciale, C., Scharfman, H. E., & Schwarcz, R. M. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00030-0 · Cited by 80
Self-citationPATHOLOGIC CHANGES IN HUNTINGTON'S CHOREA: WITH SPECIAL REFERENCE TO THE CORPUS STRIATUM
Dunlap, C. B. (1927) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1927.02210060002001 · Cited by 75
Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington's disease
Heyes, M. P., Swartz, K. J., Markey, S. P., & Beal, M. F. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90874-s · Cited by 69
Ionotropic Glutamate Receptors as Therapeutic Targets
Jellinger, K. A. (2004) · European Journal of Neurology · doi:10.1111/j.1468-1331.2004.00786.x · Cited by 67
Mechanisms of transcriptional dysregulation in Huntington's disease
Luthi‐Carter, R., & Cha, J.-H. J. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00059-8 · Cited by 60
Self-citationHypoxic induction of caspase-11/caspase-1/interleukin-1β in brain microglia
Kim, N.-G., Lee, H., Son, E., Kwon, O.-Y., Park, J., Park, J.-H., Cho, G. J., Choi, W. S., & Suk, K. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00135-9 · Cited by 59
Modulation of N-methyl-d-aspartate receptors by hydroxyl radicals in rat cortical neurons in vitro
Aizenman, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11442-y · Cited by 48
Feany, M. Β., & Spada, A. R. L. (2003) · Neuron · doi:10.1016/s0896-6273(03)00600-7 · Cited by 37
MacGibbon, G. A., Hamilton, L. C., Crocker, S. F., Costain, W. J., Murphy, K. M., Robertson, H. A., & Denovan‐Wright, E. M. (2002) · Journal of Neuroscience Research · doi:10.1002/jnr.10100 · Cited by 23
Cited by
Kynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Self-citationMolecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence?
Lewerenz, J., & Maher, P. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00469 · Cited by 718
Kynurenines in the CNS: recent advances and new questions
Vécsei, L., Szalárdy, L., Fülöp, F., & Toldi, J. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3793 · Cited by 641
Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration
Zwilling, D., Huang, S.-Y., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H.-Q., Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.020 · Cited by 515
Self-citation
Metadata
- Authors
- GUIDETTI, P., LUTHICARTER, R., AUGOOD, S., & SCHWARCZ, R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2004-12
- Volume
- 17
- Issue
- 3
- Pages
- 455-461
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W1971242889
- Cited by
- 260
- References
- 55
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.